China Pharma Outsourcing Annual Review 2009

It has been well recognized that 2009 is a rough year to all types of industries worldwide. The financial crisis has significantly altered both pharmaceutical and biotechnology industries on global scale. The pharma outsourcing industry, both globally and in China, has also been significantly affected. The Chinese pharma outsourcing industry suffered a significant setback in 2009 if compared with the growth path of all its previous years.

However, even though a significant decrease in outsourcing demand was seen in almost every service sector of the Chinese pharma outsourcing industry, its growth rate in 2009 is still so significant that could make many of its rivals envy. In addition to the numerous advantages China still possesses in pharma outsourcing, a number of new factors also contributed to the further growth of the Chinese industry in 2009.

Encouraged by a large number of organizations and professionals that are interested in this Chinese industry and that are eagerly seeking clues of how the Chinese industry has been doing under the shadow of the global financial crisis and how it will likely move in 2010, in this Annual Review, we present the latest update of our research results on this Chinese industry.

The Review starts with our in-depth analysis of how the global pharma and biotech industries have been affected by the crisis and the impacts of these changes on the global pharma outsourcing. It is then followed by our detailed analysis of how the Chinese pharma outsourcing industry has weathered the storm in the last twelve months or so.

The Review also well summarized all major events happened in 2009 including the outsourcing activities in China by drug companies from all over the world, both major pharma and R&D-focused biotech companies.

Also presented in the Review are the outlooks, based on our in-depth analysis and study, of how the global pharma outsourcing in general and the Chinese pharma outsourcing in specific will likely move in 2010.

The most distinct feature of the Review is the inclusion of the current top ten professional pharma outsourcing service providers in the Chinese pharma outsourcing industry, including the detailed description and company profile of each player. To the best of our knowledge, this is the first time that the top ten players of the Chinese pharma outsourcing industry are successfully identified.

The Review will help readers not only gain a clear and deep insight into what has happened to the Chinese pharma outsourcing industry in the past year but also better understand how it will likely move next year. It is a must-read book to all organizations and professionals in the industries of pharmaceutical, biotechnology, outsourcing service and financial investment that are interested in pharmaceutical outsourcing in China.